Consult Lhasa

📹Did you catch our previous video on how Consult Lhasa can support you in classifying potentially mutagenic impurities (PMIs)? 💡In part two, Lead Scientific Consultant, Roberta L. Drekener and Scientific Consultant, Michael Burns share key insights into how we can help you to define your PMI control strategy. Learn more about how Consult Lhasa can support your risk assessments: https://buff.ly/4g1aN7u

Do you need help assessing your nitrosamine impurities? ➡️ Swipe right to learn how Consult Lhasa can help. Discover more about how we can support your nitrosamine risk assessments: https://buff.ly/3UTrf1B #DrugDevelopment #Nitrosamines #Pharmaceuticals

Discover four key ways Consult Lhasa can support your classification of potentially mutagenic impurities (PMIs). 📽 In the video below, Consult Lhasa Lead Scientific Consultant, Gabriela Silveira, and Scientific Consultant, Robert Foster answer four FAQs: 💡How does Consult Lhasa undertake impurity classification? 💡What is the Consult Lhasa expert review process? 💡How does Consult Lhasa calculate an acceptable intake for an impurity? 💡What regulatory support does Consult Lhasa provide? Get in touch to discover more about the benefits of partnering with us: https://buff.ly/3AhzBsp #ChemicalSafety #DrugDevelopment #PharmaSafety

If you're looking for help defining the impurity profile of your active pharmaceutical ingredient (API) or drug product, we can help. At Consult Lhasa, we combine expert knowledge with trusted Lhasa Limited software predictions to identify impurities arising within drug development, supporting safe final products that meet regulatory requirements. 💬 Contact us for expert guidance: https://buff.ly/3AhzBsp #pharmasafety #riskassessment #drugdevelopment #impurity

If you're looking for expert scientific risk assessments which are recognised and trusted by industry and regulatory authorities, Consult Lhasa can help. Read how we’ve supported Muzaffar Khan, Senior General Manager of Regulatory Affairs at Laurus Labs Limited, through our partnership: https://buff.ly/3SNxMts #leachables #mutagenicimpurities #nitrosamines

Do you need help assessing your nitrosamine impurities? 📽 In the video below, Consult Lhasa Lead Scientific Consultant, David Ponting, and Scientific Consultant, Jack Yung, PhD answer some FAQs, including:   💡 How can Consult Lhasa help me to define an acceptable limit for my nitrosamine impurity? 💡How does Consult Lhasa use Lhasa Limited software solutions in risk assessments? 💡What regulatory support can Consult Lhasa provide?   Get in touch for expert guidance: https://buff.ly/3AhzBsp #DrugDevelopment #Nitrosamines #Pharmaceuticals

Curious to know more about how partnering with Consult Lhasa could help you? 💬 We asked Adriana Tomalino, Head of Regulatory Affairs at TRIQUIM, about her experience of working with our expert team. Find out more from our #ConsultLhasaCommunity and get in touch: https://buff.ly/3SNxMts #DrugDevelopment #MutagenicImpurities #nitrosamines #rdc53

If you're looking for help defining the impurity profile of your active pharmaceutical ingredient (API) or drug product, we can help. At Consult Lhasa, we combine expert knowledge with trusted Lhasa Limited software predictions to identify impurities arising within drug development, supporting safe final products that meet regulatory requirements. 💬 Contact us for expert guidance: https://buff.ly/3AhzBsp #pharmasafety #riskassessment #drugdevelopment #impurity

Join the Consult Lhasa community! Sign up for our #newsletter to stay up to date with the latest insights and more 📩: https://buff.ly/40doYl4

How do we ensure high quality risk assessments, in line with regulatory requirements? At Consult Lhasa, our consultants provide expert guidance across four key areas: ✅ Impurity formation ✅ Potentially mutagenic impurities ✅ Non-mutagenic impurities ✅ Nitrosamines We ensure our risk assessments are of the highest quality by involving multiple domain experts - ensuring a fully considered assessment. Find out more and get in touch for trusted guidance: https://buff.ly/3AhzBsp #pharmasafety #riskassessment #drugdevelopment